Circio selected for oral presentation at ESGCT 2024 annual meeting
- Circio has been selected to present its circVec circular RNA expression platform at the European Society of Cell and Gene Therapy (ESGCT) annual meeting 2024, taking place on 22-25 October 2024 in Rome, Italy
- ESGCT is one of the most prestigious and widely attended international conferences in the gene therapy field
- In the presentation, Circio wil showcase the latest developments and in vivo data for its circVec circular RNA expression platform designed to enhance gene therapy
Oslo, Norway 24 September 2024 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing next generation circular RNA vector technology for gene therapy, today announces that a scientific abstract submitted to the European Society of Cell and Gene Therapy (ESGCT) annual meeting 2024 has been selected for oral presentation. The presentation will be given by Circio´s CTO, Dr. Thomas B Hansen on 23 October 2024.
“Circio´s unique and powerful circVec platform keeps building momentum, and we are very excited to be selected to present our technology at the prestigious ESGCT meeting.” said Dr. Thomas B. Hansen, CTO of Circio “This meeting provides a great opportunity to showcase how the latest circVec generation continues to significantly outperform mRNA-based expression, thereby delivering a substantial improvement over current gold-standard gene therapy approaches.”
The ESGCT invitation follows recent presentations at several RNA industry conferences and coverage in international life science media, highlighting the advantages and potential of circular RNA therapeutics and reinforcing Circio´s position as a leader in this rapidly emerging field.
Title of presentation:
Optimization of in vitro and in vivo performance of circVec, a vector-based circular RNA expression platform for enhanced gene therapy
Presenter:
Dr. Thomas B Hansen, CTO
Time and location:
23 October 2024 @ 19:30hrs CET - Rome, Italy
For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com
About Circio
Building next generation RNA therapeutics
Circio Holding ASA is a biotechnology company developing novel circular RNA and immunotherapy medicines.
Circio has established a unique circular RNA (circRNA) platform for genetic medicine. The proprietary circVec technology is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA from DNA and viral vectors, which can be deployed in multiple disease settings. The circVec platform has demonstrated enhanced and more durable protein expression than classic mRNA vector systems, and has the potential to become the new gold-standard for DNA and virus-based therapeutics in the future. The circRNA R&D activities are being conducted by the wholly owned subsidiary Circio AB based at the Karolinska Institute in Stockholm, Sweden.